Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06008197 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
A Phase 3 study of Heart Failure and Acute Heart Failure, sponsored by Colorado Prevention Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 5,200
- Enrollment target
- 20
- Study locations
NCT06008197: Recruiting Phase 3 study of Heart Failure and Acute Heart Failure, sponsored by Colorado Prevention Center.
NCT06008197 is a Phase 3 study of Heart Failure and Acute Heart Failure that is actively recruiting participants, run by Colorado Prevention Center. The registered enrollment target is 5,200 participants, above the 2,036-participant average among 397 other Heart Failure trials with a reported enrollment target (155% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06008197, a Phase 3 study of Heart Failure and Acute Heart Failure, is actively recruiting participants, sponsored by Colorado Prevention Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 5,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
Primary Outcome
Total (first and subsequent) HF hospitalizations, urgent visits for worsening HF, and CV deaths with finerenone compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Finerenone
Study Locations (20)
Indiana
- Indianapolis, IN Investigative Site 10074 - Indianapolis
- Indianapolis, IN Investigative Site 10008 - Indianapolis
- Merrillville, IN Investigative Site 10064 - Merrillville
Kentucky
- Louisville, KY Investigative Site 10006 - Louisville
- Louisville, KY Investigative Site 10086 - Louisville
- Paducah, KY Investigative Site 10079 - Paducah
California
- Huntington Beach, CA Investigative Site 10031 - Huntington Beach
- Los Angeles, CA Investigative Site 10089 - Los Angeles
Florida
- Brooksville, FL Investigative Site 10077 - Brooksville
- Miramar, FL Investigative Site 10113 - Miramar
Ohio
- Centerville, OH Investigative Site 10119 - Centerville
- Cincinnati, OH Investigative Site 10088 - Cincinnati
Arizona
- Glendale, AZ Investigative Site 10096 - Glendale
Idaho
- Boise, Idaho Investigative Site 10073 - Boise
Illinois
- Chicago, IL Investigative Site 10062 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,200 participants |
| Start Date | 2024-01-17 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
What NCT06008197 shows while recruiting
NCT06008197 is an interventional study that assigns participants to a tested intervention. Its 5,200 participants enrollment target places it among the larger protocols in the corpus, above the 2,036-participant average among 397 other Heart Failure trials with a reported enrollment target (155% higher).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06008197 names 20 study sites across 13 states, led by Indiana, Kentucky, California.
Frequently Asked Questions
What is clinical trial NCT06008197 about?
NCT06008197 is a clinical study titled "A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients". Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
What is the current status of trial NCT06008197?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,200 participants. The study started on 2024-01-17. Estimated completion is 2027-12.
What conditions does trial NCT06008197 study?
This clinical trial studies the following conditions: Heart Failure, Acute Heart Failure.
What interventions are being tested in trial NCT06008197?
The interventions under investigation include: Placebo (DRUG), Finerenone (DRUG).
Who is sponsoring clinical trial NCT06008197?
This trial is sponsored by Colorado Prevention Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06008197 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06008197's enrollment target sits among peer trials
5,200 18th of 397 higher than 380 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05989308 · 5,200 participants · NA
MyChart Proxy Outreach to Parents (MyPOP)
- NCT05135403 · 5,179 participants
ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
- NCT06535867 · 5,122 participants
The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI